NOX to start cancer-busting trials by year’s end
Noxopharm (ASX:NOX) has confirmed it is on track to start clinical trials of its lead cancer drug, NOX66, in Europe by the end of the year.
It told its shareholders this morning that it had put the logistics in place to start a progressive 1a, 1b, and possibly 2a phase trial of its drug in Georgia.
It has designed the trial in three phases, testing different dosage and combinations in each.
In phase 1a, 15 patients will dosed with NOX66 alone.
In phase 1b, patients will be dosed using NOX66 and carboplatin – testing various cancer types.
If 1b is successful, NOX will then move onto 2a which will involve “a specific dosage of NOX66 + carboplatin” in specific types of cancer. Phase 2a will involve the recruitment of another 20 patients.
All trial candidates will have solid cancers which have been proven to be unresponsive to standard cytotoxic chemotherapy.
The primary objectives of the trials are to make sure that NOX66 is safe on its own, and in combination with carboplatin.
The hope is that NOX66 will be able to lower the tumour’s resistance to carboplatin – which can be an issue in unresponsive tumours.
Data and statistics for the trial will be run by Australian company Datapfarm Australia, while UK-based Clinical Accelerator will be responsible for managing the study.
There is no guarantee that the trials will prove a success, and investors should always consult a professional financial advisor before deciding whether or not to invest.
About NOX and NOX66
NOX66 is designed as an innovative dosage formulation of idronoxil, a compound which down-regulates pro-survival mechanism in cancer cells – including the cell’s ability to establish and maintain a range of drug-resistant mechanisms.
This can be an issue when it comes to treating solid tumours with chemotherapy, as the cells are able to resist treatment.
In particular, NOX66 has been formulated to target “tumour-specific external NADH oxidase-2”, which is the protein responsible for maintaining the transmembrane electron potential in the cancer cell’s plasma membrane.
It is thought by eliminating this, the cancer cells loses the ability to maintain a wide-range of pro-survival mechanisms.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.